Arena Pharmaceuticals, Inc. (ARNA): Price and Financial Metrics


Arena Pharmaceuticals, Inc. (ARNA): $61.23

-1.45 (-2.31%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add ARNA to Watchlist
Sign Up

Industry: Biotech


Ranked

of 493

in industry

ARNA POWR Grades


  • Quality is the dimension where ARNA ranks best; there it ranks ahead of 38.56% of US stocks.
  • The strongest trend for ARNA is in Growth, which has been heading down over the past 200 days.
  • ARNA ranks lowest in Momentum; there it ranks in the 7th percentile.

ARNA Stock Summary

  • The capital turnover (annual revenue relative to shareholder's equity) for ARNA is 0 -- better than just 7.49% of US stocks.
  • ARNA's price/sales ratio is 66,744.52; that's higher than the P/S ratio of 99.98% of US stocks.
  • As for revenue growth, note that ARNA's revenue has grown -98.99% over the past 12 months; that beats the revenue growth of only 0.68% of US companies in our set.
  • If you're looking for stocks that are quantitatively similar to Arena Pharmaceuticals Inc, a group of peers worth examining would be OCGN, BLU, NYMX, INMB, and CYAD.
  • Visit ARNA's SEC page to see the company's official filings. To visit the company's web site, go to www.arenapharm.com.

ARNA Price Target

For more insight on analysts targets of ARNA, see our ARNA price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $98.07 Average Broker Recommendation 1.33 (Strong Buy)

ARNA Stock Price Chart Interactive Chart >

Price chart for ARNA

ARNA Price/Volume Stats

Current price $61.23 52-week high $90.19
Prev. close $62.68 52-week low $44.79
Day low $61.03 Volume 424,379
Day high $63.72 Avg. volume 501,059
50-day MA $69.14 Dividend yield N/A
200-day MA $72.54 Market Cap 3.72B

Arena Pharmaceuticals, Inc. (ARNA) Company Bio


Arena Pharmaceuticals is a biopharmaceutical company focused on discovering, developing and commercializing drugs to address unmet medical needs. The company was founded in 1997 and is based in San Diego, California.


ARNA Latest News Stream


Event/Time News Detail
Loading, please wait...

ARNA Latest Social Stream


Loading social stream, please wait...

View Full ARNA Social Stream

Latest ARNA News From Around the Web

Below are the latest news stories about Arena Pharmaceuticals Inc that investors may wish to consider to help them evaluate ARNA as an investment opportunity.

Arena Pharmaceuticals, Inc. (ARNA) CEO Amit Munshi on Q1 2021 Results - Earnings Call Transcript

Arena Pharmaceuticals, Inc. (ARNA) Q1 2021 Earnings Conference Call May 05, 2021, 16:30 ET Company Participants Patrick Malloy - VP, IR & Corporate Communications Amit Munshi - President, CEO & Director Laurie Stelzer - EVP & CFO Conference Call Participants Kennen MacKay - RBC Capital Markets Chi Meng Fong -...

SA Transcripts on Seeking Alpha | May 6, 2021

Arena (ARNA) Q1 Earnings Beat Estimates, Etrasimod Progresses

Arena Pharmaceuticals (ARNA) beats Q1 bottom-line estimates. The company progresses with the development of its key pipeline candidate, etrasimod.

Yahoo | May 6, 2021

Arena Pharmaceuticals Inc (ARNA) Q1 2021 Earnings Call Transcript

Joining me on today's call are Amit Munshi, our President and Chief Executive Officer; and Laurie Stelzer, our Chief Financial Officer. Before we begin, I'd like to remind you that we'll be making forward-looking statements that involve risks and uncertainties about our goals, expectations, plans, beliefs, timing of events or future results, including those risks and uncertainties related to our pipeline, financial projections, 2021 financial guidance and the COVID-19 pandemic and its potential impact on our business.

Yahoo | May 6, 2021

Arena Pharmaceuticals, Inc. (ARNA) Reports Q1 Loss, Misses Revenue Estimates

Arena Pharmaceuticals, Inc. (ARNA) delivered earnings and revenue surprises of 9.59% and -100.00%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

Yahoo | May 5, 2021

Arena Reports First Quarter Financial Results with Strong Cash Position and Continued Progress on Pipeline Over the Quarter

Arena Pharmaceuticals today provided a corporate update and reported financial results for the first quarter ended March 31, 2021.

Yahoo | May 5, 2021

Read More 'ARNA' Stories Here

ARNA Price Returns

1-mo -5.45%
3-mo -26.34%
6-mo -8.17%
1-year 21.10%
3-year 36.10%
5-year 300.20%
YTD -20.30%
2020 69.15%
2019 16.61%
2018 14.66%
2017 139.23%
2016 -25.26%

Continue Researching ARNA

Want to see what other sources are saying about Arena Pharmaceuticals Inc's financials and stock price? Try the links below:

Arena Pharmaceuticals Inc (ARNA) Stock Price | Nasdaq
Arena Pharmaceuticals Inc (ARNA) Stock Quote, History and News - Yahoo Finance
Arena Pharmaceuticals Inc (ARNA) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.9175 seconds.